<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00001300 on 2006_07_14: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00001300">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00001300">&#8593; Current version of this study</a></div><h1>View of NCT00001300 on
  2006_07_14</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00001300</td>
</tr>
<tr>
<th>Updated:</th><td>2006_07_14</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Randomized study. &nbsp;All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.<br>
<br>
<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regimen A: &nbsp;Surgery followed, as indicated, by Radiotherapy. &nbsp;Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.<br>
<br>
<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arm I: &nbsp;2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection. &nbsp;Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,<br>
<br>
<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NSC-614629; and Mesna, NSC-113891.<br>
<br>
<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arm II: &nbsp;Observation. &nbsp;No adjuvant chemotherapy.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively. &nbsp;Local recurrence, disease-free survival and overall survival will be evaluated in this randomized two-arm trial.</p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Efficacy Study</td>
</tr>
<tr>
<th>Condition</th><td>
         Sarcoma
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: doxorubicin</div>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: ifosfamide</div>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: mesna</div>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349-59.</div>
<div>MEDLINE: 3566372</div>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A, et al.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989 Oct;7(10):1504-13.</div>
<div>MEDLINE: 2674336</div>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN Jr, Sugarbaker PH, Lack EE, Steinberg SM, et al.  Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988 Sep;6(9):1491-500.</div>
<div>MEDLINE: 3047339</div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            Completed
         </td>
</tr>
<tr>
<th>Start date</th><td>
         1992-06
      </td>
</tr>
<tr>
<th>End date</th><td>
         2001-03
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>DISEASE CHARACTERISTICS:<br>
<br>Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous Ewing's sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.<br>
<br>Confirmed presence of tumor-specific infusion protein by documented RT-PCR which corresponds to one of the tumor specific peptides available for vaccination.<br>
<br>Measurable tumor.<br>
<br>No prior or current CNS metastases.<br>
<br>PRIOR/CONCURRENT THERAPY:<br>
<br>Arm A patients:<br>
<br>May be enrolled on the protocol for the first phase in the absence of RT PCR documentation of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides available for vaccination. &nbsp;However, RT PCR documentation at the time of tumor recurrence must occur prior to administration of immunotherapy. At time of initial tumor diagnosis, prior to any cytoreductive therapy.<br>
<br>Arm B patients:<br>
<br>Tumor recurrence occurring during or after receiving at least first line cytoreductive therapy for ESFT and AR. &nbsp;No more than two post-recurrence salvage regimens unless peripheral CD4+T &nbsp;cell number is greater than 400 cells per millimeter cubed.<br>
<br>At least 6 weeks since any treatments and recovered from all acute toxic effects from time in which immunotherapy will be started for this study.<br>
<br>No concurrent estrogen therapy during immunotherapy section of study.<br>
<br>PATIENT CHARACTERISTICS:<br>
<br>Age: &nbsp;2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).<br>
<br>Weight: &nbsp;Greater than 15 kg (at time of apheresis).<br>
<br>Performance status: &nbsp;ECOG 0-2.<br>
<br>Life expectancy: &nbsp;At least 8 weeks.<br>
<br>Hematopoietic:<br>
<br>ANC greater than 100,000/mm3.<br>
<br>Hemoglobin greater than 9.0 g/dL.<br>
<br>Platelet count greater than 50,000/mm3.<br>
<br>Hepatic:<br>
<br>Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).<br>
<br>Transaminases less than 3 times normal (unless related to involvement by tumor).<br>
<br>Renal:<br>
<br>Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.<br>
<br>Cardiovascular:<br>
<br>No major disorder of cardiovascular system.<br>
<br>Cardiac ejection fraction greater than 40%.<br>
<br>Pulmonary:<br>
<br>No major disorder of pulmonary system.<br>
<br>Other:<br>
<br>Not pregnant or nursing.<br>
<br>HIV negative.<br>
<br>Hepatitis B or C negative.<br>
<br>No patients requiring daily oral corticosteroid therapy.<br>
<br>If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome, ineligible to receive influenza vaccine.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>N/A</td>
</tr>
<tr>
<th>Maximum age</th><td>N/A</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>150</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>National Institutes of Health Clinical Center (CC)</td>
</tr>
<tr>
<th>Organization study ID</th><td>920210</td>
</tr>
<tr>
<th>Secondary ID</th><td>
            92-C-0210
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               National Cancer Institute (NCI)
            </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
